latest news releases from the newsroom
Icagen Initiates Study of Senicapoc in Exercise Induced Asthma
RESEARCH TRIANGLE PARK, N.C., March 11, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a Phase II proof-of-concept study of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients with exercise-induced asthma. This study complements an ongoing proof-of-concept study in patients with allergic asthma which the Company initiated during the fourth quarter of 2008.
Icagen Reports Fourth Quarter and Full Year 2008 Financial Results
RESEARCH TRIANGLE PARK, N.C., March 11, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today its financial results and operational highlights for the fourth quarter and full year ended December 31, 2008. For the fourth quarter of 2008, the Company reported revenues of $3.0 million and a net loss of $3.9 million. For the full year 2008, the Company reported revenues of $12.3 million and a net loss of $14.8 million. As of December 31, 2008, the Company's cash and cash equivalents totaled $34.2 million.
Avigen's Board Urges Stockholders to Reject BVF's Proposal
ALAMEDA, Calif., March 11, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today announced that it has scheduled a Special Meeting of Stockholders as requested by Biotechnology Value Fund, L.P. (BVF). Information about the meeting can be found in Avigen's Definitive Proxy Statement filed with the Securities and Exchange Commission on March 9, 2009 and mailed to stockholders on March 10, 2009.
TearLab Initiates International Clinical Study of TearLab(tm) Osmolarity System
SAN DIEGO, March 11, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has initiated an international clinical study which is designed to demonstrate the efficacy of the TearLab(tm) Osmolarity System as a practical tool for the diagnosis and assessment of severity of Dry Eye Disease (DED) by measuring the osmolarity of tears. Osmolarity, simply stated, is a measure of the concentration of particles or solute per liter of solution.
Medicis Pharmaceutical Corporation
Medicis Declares Cash Dividend
SCOTTSDALE, Ariz., March 11, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that its Board of Directors declared a quarter-end cash dividend of $0.04 per issued and outstanding share of its Common Stock payable on April 30, 2009, to stockholders of record at the close of business on April 1, 2009.